Several factors involved in success of repeat corneal grafts

Article

There are several factors involved in the success of repeat penetrating corneal transplantation for keratoconus patients.

A study featured in Ophthalmology has confirmed there are several factors involved in the success of repeat penetrating corneal transplantation for keratoconus patients. These factors include duration of success of initial graft, age of patient, location of surgery and post-op rejection and corneal neovascularization.

A large cohort investigation led by Dr Keryn A. Williams, Department of Ophthalmology, Flinders Medical Centre, Bedford Park, Australia, included 229 regrafts from a national register of corneal grafts. The study involved 177 eyes of 173 patients and regrafts that had been performed more than once in 16 eyes. The main outcome measure was graft survival- analysed using Kaplan-Meier plots and Cox proportional hazards regression.

It was found that graft survival was significantly worse for second and third grafts compared to the first keratoconus graft. Kaplan-Meier survival plots were 88%, 69% and 46% at 1, 5 and 15 years postgrafting for seconds grafts, respectively. For the third grafts the Meier survival plots were 65%, 49% and 33% at 1, 5 and 15 years postgrafting, respectively.

The risk factors linked to graft failure of repeat grafts included the surgery location, failure of the previous graft within 10 years of surgery, rejection episodes and corneal neovascularization postoperatively.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.